Footnotes

• LS and CJR are joint senior authors.

• Contributors CR, RCF, LS and LJN conceived and designed the study. ID-B and JD undertook participant recruitment. JD undertook qualitative interviews. JD, LS and LJN undertook qualitative analysis. JD, LS, LJN and CR adapted PREM according to analysis. All authors contributed to this letter.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Competing interests LJN, LS and CR have received grant funding from Medtronic. LS and CR have received grant funding from 3D Matrix solutions. CJR has received grant funding from ARC medical, Norgine and Olympus medical. He was an expert witness for ARC medical and Olympus medical. RCF is named on patents related to Cytosponge and associated assays that have been licensed to Covidien (now Medtronic). RCF is a founder and <8% shareholder of Cyted Ltd. ID-B and JD have no conflicts to declare.

• Provenance and peer review Not commissioned; internally peer reviewed.

• Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.